Deals
Four Firms Advise on the Teva-Allergan Deal: Business of Law
This article is for subscribers only.
Israeli drugmaker Teva Pharmaceuticals Industries Ltd. agreed to buy the generic-drug business of Allergan Plc for about $40.5 billion in cash and stock and ended its hostile bid for Mylan NV.
Sullivan & Cromwell LLP represents Teva, while Latham & Watkins LLP is primary counsel for Allergan. In addition, Cleary Gottlieb Steen & Hamilton LLP advised Allergan on international competition law matters outside the U.S. and Canada and certain financing-related matters, and Weil, Gotshal & Manges LLP is representing Allergan on antitrust aspects of the deal.